303 related articles for article (PubMed ID: 28040690)
41. Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study.
Schmidt B; Debold E; Frank M; Arendt M; Dragano N; Dürig J; Dührsen U; Moebus S; Erbel R; Jöckel KH; Eisele L
Ann Hematol; 2019 Dec; 98(12):2761-2767. PubMed ID: 31691002
[TBL] [Abstract][Full Text] [Related]
42. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.
Greenberg AJ; Vachon CM; Rajkumar SV
Leukemia; 2012 Apr; 26(4):609-14. PubMed ID: 22193966
[TBL] [Abstract][Full Text] [Related]
43. Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Br J Cancer; 2017 Sep; 117(6):835-839. PubMed ID: 28728165
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study.
Gupta R; Dahiya M; Kumar L; Shekhar V; Sharma A; Ramakrishnan L; Sharma OD; Begum A
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e345-e350. PubMed ID: 29980412
[TBL] [Abstract][Full Text] [Related]
45. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.
Dhodapkar MV; Sexton R; Hoering A; Van Rhee F; Barlogie B; Orlowski R
Clin Cancer Res; 2020 Nov; 26(22):5814-5819. PubMed ID: 32816893
[TBL] [Abstract][Full Text] [Related]
46. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
47. Vitamin D and monoclonal gammopathy of undetermined significance (MGUS) among U.S. Black women.
Ruiz Lopez JN; McNeil GE; Zirpoli G; Palmer JR; Kataria Y; Bertrand KA
Cancer Causes Control; 2024 Feb; 35(2):277-279. PubMed ID: 37707565
[TBL] [Abstract][Full Text] [Related]
48. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
[TBL] [Abstract][Full Text] [Related]
49. Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study.
Ashruf OS; Orozco Z; Kaelber DC
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):626-632. PubMed ID: 37208255
[TBL] [Abstract][Full Text] [Related]
50. Identifying monoclonal gammopathy of undetermined significance from electronic health records.
Tanenbaum HC; Birmann BM; Bertrand KA; Teras LR; Krishnan AY; Pourhassan H; Goldsmith S; Cannavale K; Wang SS; Chao CR
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1755. PubMed ID: 36464325
[TBL] [Abstract][Full Text] [Related]
51. [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients].
Salgado C; Bladé J; López-Guillermo A; Cervantes F; Montserrat E; Rozman C
Sangre (Barc); 1993 Oct; 38(5):371-4. PubMed ID: 8140498
[TBL] [Abstract][Full Text] [Related]
52. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
53. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
[TBL] [Abstract][Full Text] [Related]
54. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.
Kristinsson SY; Fears TR; Gridley G; Turesson I; Mellqvist UH; Björkholm M; Landgren O
Blood; 2008 Nov; 112(9):3582-6. PubMed ID: 18559977
[TBL] [Abstract][Full Text] [Related]
55. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
56. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Sandecká V; Hájek R; Pour L; Špička I; Ščudla V; Gregora E; Radocha J; Walterová L; Kessler P; Zahradová L; Adamová D; Valentova K; Vonke I; Obernauerová J; Starostka D; Wróbel M; Brožová L; Jarkovský J; Mikulášová A; Říhová L; Ševčíková S; Straub J; Minařík J; Adam Z; Krejčí M; Král Z; Maisnar V;
Eur J Haematol; 2017 Jul; 99(1):80-90. PubMed ID: 28384387
[TBL] [Abstract][Full Text] [Related]
57. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.
McShane CM; Murray LJ; Landgren O; O'Rorke MA; Korde N; Kunzmann AT; Ismail MR; Anderson LA
Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):332-42. PubMed ID: 24451437
[TBL] [Abstract][Full Text] [Related]
58. Differences in Hospital, Emergency Room and Outpatient Visits Among Adults With and Without Monoclonal Gammopathy of Undetermined Significance.
Castañeda-Avila MA; Lapane KL; Person SD; Jesdale BM; Zhou Y; Mazor KM; Epstein MM
Cancer Control; 2022; 29():10732748221126936. PubMed ID: 36112886
[TBL] [Abstract][Full Text] [Related]
59. What is the significance of monoclonal gammopathy of undetermined significance?
Atkin C; Richter A; Sapey E
Clin Med (Lond); 2018 Oct; 18(5):391-396. PubMed ID: 30287433
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Iwanaga M; Tomonaga M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
